Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | +0.62% | +7.31% | +13.73% |
02-14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
02-14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.73% | 17.87M | |
+31.18% | 695B | |
+26.51% | 568B | |
-4.58% | 361B | |
+19.70% | 330B | |
+3.85% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.92% | 168B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party